Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Medicine (Baltimore) ; 94(39): e1490, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26426611

ABSTRACT

The purpose of this study was to identify the factors that predict incomplete low-dose radioiodine remnant ablation (RRA) with recombinant human thyroid-stimulating hormone (rhTSH) and to report the adverse events associated with this treatment. Between 2012 and 2014, 43 consecutive patients with thyroid cancer received low-dose RRA with rhTSH after total thyroidectomy. We retrospectively investigated the adverse events during low-dose RRA and during diagnostic whole body scan (DxWBS) using rhTSH, and analyzed the rate of RRA completion and the associations between RRA completion and various clinical/pathological factors. Complete RRA was seen in 33 (76.7%) patients, and incomplete RRA was observed in 10 (23.3%). Patients with incomplete RRA had stronger neck accumulation of 131I than those with complete RRA (P < 0.001). Adverse events at RRA and DxWBS were seen in 12 and 9 patients, respectively. All events at RRA were grade 1, with one exception (grade 2 vertigo after rhTSH administration). The rate of adverse events at DxWBS was significantly higher in patients with adverse events seen at RRA (risk ratio, 3.778, P = 0.008). Strong neck accumulation of 131I is significant independent predictor of incomplete low-dose RRA. The risk of adverse events at DxWBS was higher in patients who experienced adverse events at RRA than in those who did not.


Subject(s)
Carcinoma/drug therapy , Iodine Radioisotopes/therapeutic use , Thyroid Neoplasms/drug therapy , Thyrotropin/therapeutic use , Adult , Aged , Aged, 80 and over , Carcinoma/surgery , Drug Therapy, Combination , Female , Humans , Iodine Radioisotopes/pharmacokinetics , Male , Middle Aged , Neck , Recombinant Proteins/therapeutic use , Retrospective Studies , Thyroid Neoplasms/surgery , Thyroidectomy
2.
J Nucl Cardiol ; 9(6): 622-31, 2002.
Article in English | MEDLINE | ID: mdl-12466787

ABSTRACT

BACKGROUND: Technetium 99m-labeled radiopharmaceuticals accumulate in the liver and gallbladder, where they generate intensity artifacts that can result in misdiagnosis of myocardial single photon emission computed tomography (SPECT) images. This study identifies and eliminates factors affecting the magnitude and appearance of intensity artifacts in a gallbladder-heart phantom. METHODS AND RESULTS: The myocardium and background compartments of a phantom were filled with Tc-99m at concentrations of 320 and 26.1 kBq/mL, respectively. A disposable plastic syringe containing 5 mL of Tc-99m as a model of the gallbladder was fixed in a position lateral to the heart phantom. Artifact intensity was determined on SPECT images over a specific activity range in the syringe (28.6, 6.6, and 0.2 MBq/mL). Among 72 projection images, those with maximal heart counts in the region of interest were selected. Counts above and below 110% of the maximal heart count in all projection images were excluded and reconstructed, respectively. At 28.6 and 6.6 MBq/mL, excessive artifacts generated cold pixels immediately around the source, whereas lower activity (0.2 MBq/mL) caused the artifacts to disappear. Truncating the counts in the gallbladder caused the intensity artifacts at specific activities of 28.6 and 6.6 MBq/mL to disappear. CONCLUSIONS: The magnitude and appearance of intensity artifacts depend on contrast between extracardiac activities in the same slices of the heart in myocardial SPECT images with Tc-99m tetrofosmin, and pixel truncation can eliminate them.


Subject(s)
Artifacts , Gallbladder/diagnostic imaging , Heart/diagnostic imaging , Image Enhancement/methods , Phantoms, Imaging , Tomography, Emission-Computed, Single-Photon/methods , Humans , Image Enhancement/instrumentation , Organophosphorus Compounds , Organotechnetium Compounds , Quality Control , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Tomography, Emission-Computed, Single-Photon/instrumentation
SELECTION OF CITATIONS
SEARCH DETAIL
...